Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine.Details of the agreement, which was finalized in federal court in Maryland this month, aren’t public. The Lacks family and Swiss-based Novartis said in a joint statement that they are “pleased they were able to find a way to r ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success and recognition in the field [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the efficacy of setrusumab (UX 143) in reducing fracture rates in patients with Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increases bone density, this does not correlate with a decrease in fracture rates, and the studies were less likely to demonstrate the claimed results than management suggested [6]. - The misleading statements allegedly led to investors purchasing shares at inflated prices, resulting in damages when the true information became public [6].

Core Viewpoint - An investigation has been launched into potential breaches of fiduciary duty by the directors, officers, and controlling shareholder of Mister Car Wash, Inc. following its announcement of a merger agreement with Leonard Green & Partners at a price significantly below its recent trading high [1] Company Overview - Mister Car Wash operates approximately 550 locations and claims to have the largest car wash subscription program in North America [1] Acquisition Details - On February 18, 2026, Mister Car Wash announced a definitive merger agreement with investment funds managed by Leonard Green & Partners, offering $7.00 per share, which represents a nearly 20% discount from the company's 52-week high [1] - Leonard Green currently owns about 67% of Mister Car Wash's outstanding shares and has secured the necessary vote for the acquisition through a "Written Consent," eliminating the need for a vote from minority stockholders [1] - If the acquisition is completed, Mister Car Wash's common stock will be delisted from the Nasdaq Global Market and deregistered under the Securities Exchange Act of 1934 [1]

Core View - The article discusses a securities fraud lawsuit against CoreWeave, Inc. (NASDAQ: CRWV) and highlights the opportunity for investors who purchased securities during the class period from March 28, 2025, to December 15, 2025, to lead the lawsuit [1] Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the court by March 13, 2026, to represent other class members in the litigation [1] - The lawsuit alleges that CoreWeave made false and misleading statements regarding its ability to meet customer demand and the risks associated with its reliance on a single third-party data center supplier [1] Allegations Against CoreWeave - The defendants allegedly overstated CoreWeave's capacity to meet customer demand [1] - The lawsuit claims that the severity of risks related to the third-party data center supplier was materially understated [1] - It is asserted that these misrepresentations were likely to have a significant negative impact on CoreWeave's revenue [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against NuScale Power Corporation, alleging material misstatements regarding its commercialization strategy for nuclear power generation projects [1] Summary by Relevant Sections Lawsuit Details - The lawsuit is filed on behalf of investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025 [1] - The deadline for investors to seek lead plaintiff status is April 20, 2026 [1] - The case is filed in the United States District Court for the District of Oregon, titled Truedson v. NuScale Power Corporation, et al, Case No. 3:26-cv-00328 (D. Or.) [1] Allegations - The complaint alleges that NuScale made false or misleading statements and failed to disclose that ENTRA1 Energy LLC had no significant experience in building or operating nuclear power projects [1] - It is claimed that NuScale entrusted its commercialization and deployment of its power module to ENTRA1, which lacked relevant experience [1] - The lawsuit also states that the qualifications attributed to ENTRA1 were actually related to the Habboush Group, another entity without significant nuclear experience [1] - As a result, NuScale's commercialization strategy faced undisclosed risks of failure, delays, and regulatory challenges [1] Financial Impact - On November 6, 2025, NuScale reported a significant increase in general and administrative expenses, which rose over 3,000% to $519 million from $17 million in the previous year [1] - This increase was largely due to a $495 million payment to ENTRA1 for a TVA agreement [1] - Consequently, NuScale's quarterly net loss surged to $532 million, compared to $46 million in the prior year [1] - Following this announcement, NuScale's stock price dropped by $5.45 per share, or approximately 14.4%, closing at $32.46 on November 6, 2025 [1] Investor Actions - Investors are advised to retain counsel or contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1] - They can also file to be lead plaintiff by the April 20, 2026 deadline [1] - The lead plaintiff will represent the class in directing the litigation and selecting counsel [1]

LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION [Accessibility Statement] Skip NavigationTime-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab EfficacyRARE INVESTOR ALERT"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "The adequacy of clinical trial risk disclosures is a fundamental issue for biopharm ...

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at $23.88 as of February 9th. Zoetis (ZTS) Hits New 52-Week Low on Dismal Outlook M. A. Arkhipov/Shutterstock.com Ultragenyx Pharmaceuticals positions itself as a diversified rare disease company with four approved products generating approximately $670 million in annual ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the efficacy of setrusumab (UX 143) in clinical trials for Osteogenesis Imperfecta, leading to inflated stock prices [5][6]. - It is claimed that while setrusumab increased bone density, it did not correlate with a decrease in fracture rates, contrary to management's assertions [6].

Core Viewpoint - PayPal Holdings, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth potential during the Class Period from February 25, 2025, to February 2, 2026 [1] Group 1: Class Action Lawsuit Details - The lawsuit, Goodman v. PayPal Holdings, Inc., claims that PayPal and certain executives violated the Securities Exchange Act of 1934 [1] - Investors who suffered substantial losses during the Class Period have until April 20, 2026, to seek appointment as lead plaintiff [1] - The lawsuit alleges that PayPal's optimistic growth plans were unrealistic and that the company minimized risks associated with macroeconomic fluctuations [1] Group 2: Financial Performance and Impact - On February 3, 2026, PayPal announced disappointing financial results for Q4 and full fiscal year 2025, including a decline in Branded Checkout performance and the withdrawal of its 2027 financial targets [1] - The announcement led to a more than 20% drop in PayPal's stock price [1] - The company attributed its poor performance to macroeconomic factors, competition, and operational issues across all regions [1] Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased PayPal common stock during the Class Period to seek lead plaintiff status [1] - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [1] - An investor's potential recovery is not contingent upon serving as lead plaintiff [1] Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years [1] - Robbins Geller is one of the largest plaintiffs' firms globally, with a history of significant securities class action recoveries [1]

Core Viewpoint - NuScale Power Corporation is facing a class action lawsuit due to alleged misleading statements regarding its commercialization partnership with ENTRA1 Energy LLC and significant financial losses reported in its recent fiscal quarter [1] Group 1: Class Action Lawsuit Details - Investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025, can seek to be lead plaintiffs in the class action lawsuit by April 20, 2026 [1] - The lawsuit alleges violations of the Securities Exchange Act of 1934 by NuScale, its executives, and Fluor Corporation [1] - The lawsuit claims that NuScale made false statements about ENTRA1's capabilities, which lacked experience in nuclear power generation [1] Group 2: Financial Impact - NuScale's general and administrative expenses surged over 3,000% to $519 million in the third fiscal quarter, up from $17 million in the previous year [1] - The company's quarterly net loss increased to $532 million, compared to $46 million in the prior year [1] - Analysts questioned NuScale's CEO about ENTRA1's qualifications during a conference call, revealing potential milestone payments exceeding $3 billion [1] Group 3: Partnership and Technology - NuScale's core technology, the NuScale Power Module (NPM), is designed for energy generation within a broader power plant [1] - The partnership with ENTRA1 was expected to advance NuScale's technology from development to deployment, validated by a joint agreement with the Tennessee Valley Authority (TVA) for up to six gigawatts of nuclear power [1]